ALS Ltd Stock
Price
Target price
€13.40
€13.40
0.000%
-
0.000%
-
17.08.26 / Frankfurt
WKN: A1J2YC / Name: ALS / Stock / Professional & Commercial Services / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for ALS
sharewise wants to provide you with the best news and tools for ALS, so we directly link to the best financial data sources.
Financials
News
Promis Neurosciences Q2 Earnings Call Highlights
Key Points
- Interested in Promis Neurosciences? Here are five stocks we like better.
- PMN310’s Phase 1b interim results showed a favorable safety profile: No ARIA-E cases, no treatment-related
Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS
Key Points
- Interested in Clene Inc.? Here are five stocks we like better.
- Clene plans to file an NDA for CNM-Au8 in early Q4 as a potential ALS treatment after five FDA meetings. The agency
Denali Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Denali Therapeutics Inc.? Here are five stocks we like better.
- AVLAYAH generated $3.6 million in its first full commercial quarter for Hunter syndrome, with payer
Amylyx Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Amylyx Pharmaceuticals, Inc.? Here are five stocks we like better.
- LUCIDITY trial results are expected in late August or early September. Amylyx has completed final
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape
Key Points
- Interested in Amylyx Pharmaceuticals, Inc.? Here are five stocks we like better.
- Amylyx expects Phase 3 topline results for avexitide in Q3 as it advances the drug for
NRx Pharmaceuticals Q1 Earnings Call Highlights
Key Points
- Interested in NRx Pharmaceuticals, Inc.? Here are five stocks we like better.
- KETAFREE moved closer to a potential summer 2026 approval after the FDA issued mostly minor review
Dutch Bros Q1 Earnings Call Highlights
Dutch Bros (NYSE:BROS) reported stronger-than-expected first-quarter results and raised its full-year outlook
Juno's Vespa Critical Minerals Discovery Expands to Include Heavy Rare Earth Magnet Metals
New Discovery Adds the Metals at the Centre of Global Supply Concerns
TORONTO, ON / ACCESS Newswire / May 19, 2026 / Juno Corp. ("Juno" or the "Company") today announced the discovery of
